This report provides an extensive analysis of the current and emerging market trends and dynamics in the market through 2023 that helps identify the upcoming market opportunities.
Portland, OR -- (SBWIRE) -- 09/19/2017 -- Salmeterol (also known as SEREVENT) is an adrenergic receptor agonist, which is mostly prescribed for the prevention and maintenance of asthma and chronic obstructive pulmonary disease. The drug has a 12-hour duration of action and thus is more beneficial than short-acting beta2- agonists, such as albuterol, which has only 4- to 6-hour duration of action.
Access to the full summary: https://www.alliedmarketresearch.com/salmeterol-market
The increase in prevalence of people suffering from asthma and COPD, low cost of the drug, and its ability in maintaining the symptoms for long duration of time is expected to increase the demand of the drug. However, certain side-effects of the drug such as dizziness, sinus infection, migraine headaches, and breathing problems restraints the market growth.
The key players operating in this market include Lupin Limited, MidasCare, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Intas Pharmaceuticals Ltd., NATCO Pharma Limited, INVENT FARMA HOLDING SPAIN S.L., Mylan N.V., Redwing Pharma, and Axa Parenterals Ltd.
Salmeterol Market Key Segments:
Get sample PDF: https://www.alliedmarketresearch.com/request-toc-and-sample/4053
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- South Africa
- Saudi Arabia
- Rest of LAMEA